The clot-buster drug, recombinant tissue plasminogen activator, is still the only pharmacological therapy available for ischemic stroke and so a greater understanding of pathophysiological mechanisms in ischemic stroke is vital to identifying potential targets and develop novel therapies (Katan & Luft, 2018). Here, PLAT is linked to ischemic stroke.